The National Heart, Lung, and Blood Institute awarded a $445,500 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to Cleveland State University, effective January 15, 2025 through December 31, 2027. The grant supports research to elucidate the role of the proteoglycan thrombomodulin (TM) and its chondroitin sulfate glycosaminoglycan (CS-GAG) in regulating the activation of protein C and thrombin activatable fibrinolysis inhibitor (TAFI), which are critical for maintaining vascular...
The National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health, awarded a $156,600 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The University of Texas Southwestern Medical Center (UT Southwestern). The 5-year grant will support research to define the role of the PHF7 protein in driving cardiac reprogramming and improving heart function following a myocardial infarction. Specifically, the project aims to: 1) Characterize...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to uncover the prevalence and biological roles of protein arginylation, a critical post-translational modification, in cardiovascular development and disease. The $633,720 award, effective January 25, 2025 through November 30, 2028, aims to: 1) establish a chemical proteomics platform to comprehensively profile arginylation sites in cardiac cell and...
This $225,600 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) aims to engineer a lab-on-a-particle platform to measure platelet function. The primary objective is to design elastic hydrogel microparticles that can assess platelet adhesion, activation, aggregation, and contraction. This innovative approach seeks to improve the reliability and reproducibility of platelet function testing and potentially...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $306,656 to Bioparin, LLC to develop biotechnological approaches for expeditious synthesis of heparin-like anticoagulants. The award aims to address the need for a reliable, modern drug production process for heparin, a critical medicine, given challenges in securing a stable supply from animal-derived sources. The project, which runs...
This $647,359 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the engineering of biomaterials with controlled biomolecule delivery for cardiovascular applications. The key products and services to be delivered include: Efficient and sustainable delivery of microRNA-145 from a novel biomaterial (PVA-CDI immobilized aminated fucoidan, or PCAF) to smooth muscle cells to induce a contractile...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $542,663.00 to Texas A&M University System Health Science Center to conduct research on the role of the small GTPase RhoE in regulating cardiac fibrosis following myocardial infarction. The research aims to define the functional significance of RhoE in post-MI cardiac remodeling and uncover novel mechanisms by which RhoE modulates extracellular matrix...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) is focused on investigating the role of the growth differentiation factor 10 (GDF10) in the maturation of cardiomyocytes during postnatal heart development. The $207,015 award to Children's Hospital Medical Center in Cincinnati, Ohio aims to determine if GDF10 signaling through activin receptors is essential for cardiomyocyte hypertrophy and mitochondrial maturation. The...
The National Heart, Lung, and Blood Institute awarded a $1,371,242 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to The University of Texas Rio Grande Valley. The 4-year grant, which runs from Sep 1, 2024 to Jun 30, 2028, will fund research to identify genetic and environmental factors underlying the high incidence of factor VIII inhibitors (FEI) in hemophilia A patients of Mexican ancestry. Key project goals include extensively characterizing a cohort of 200...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $685,884 to the University of North Carolina at Chapel Hill to conduct research on the regulation of coagulation and thrombosis by C1 inhibitor. The research aims to elucidate the molecular mechanisms by which endogenous C1 inhibitor regulates coagulation and venous thrombosis, evaluate the impact of C1 inhibitor deficiency on coagulation...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $930,481 to the University of North Texas for a 3-year research project on synthetic glycosaminoglycan mimetics as regulators of megakaryopoiesis and thrombopoiesis. The project aims to determine the nature of interaction between the non-saccharide glycosaminoglycan mimetic G4.1 and the G6B-B receptor, evaluate the selectivity of G4.1 for G6B-B, and synthesize a library of G4.1 analogs to elucidate the structure-activity relationship. This research builds on the candidate's prior experience studying glycosaminoglycan-protein interactions and organic synthesis of non-saccharide glycosaminoglycan mimetics, and leverages a well-resourced research environment and experienced advisory committee to advance the understanding of platelet production mechanisms.